Vivan Therapeutics

Vivan Therapeutics is a UK-based company specializing in genomics-based drug screening technology, aimed at personalizing cancer treatment for patients through advanced genetic analysis. Founded in 2018 and headquartered in London, UK, Vivan Therapeutics focuses on developing innovative solutions for personalized cancer treatment. The company has successfully completed one funding deal, raising USD 4. 6 mn in November 2025.

The firm has not undergone any significant pivots or changes in strategy since its inception. VivanTX offers a comprehensive genomics-based drug screening technology designed to provide personalized cancer treatment solutions. Their core product, TuMatch, analyzes the genetic and molecular profiles of tumors to identify the most effective drug combinations tailored to individual patients. This process involves whole exome sequencing (WES) of tumor biopsies and blood samples, enabling the identification of multi-gene mutations and resistance patterns in tumors.

The resulting personalized treatment recommendations are delivered through a report that prioritizes therapies based on their expected efficacy. VivanTX focuses primarily on advanced cancers such as colorectal, lung, pancreatic, and other gastrointestinal cancers, catering to patients and oncologists in the United States and select international markets. VivanTX operates on a transaction structure that centers around personalized cancer treatment consultations and the delivery of tailored drug combination reports. Clients, including oncologists and cancer patients, engage with the firm primarily through direct consultations, where patients may undergo genomic testing to generate actionable insights for their treatment.

Revenue is generated from the personalized treatment reports and consultation services, providing oncologists with the information necessary to make informed decisions about drug therapies. The company’s offerings include the TuMatch report, which encapsulates comprehensive analysis and treatment recommendations, reflecting the firm's commitment to innovative cancer care solutions. In November 2025, Vivan Therapeutics raised USD 4. 6 mn in venture funding, which will be utilized to establish cancer research labs in Abu Dhabi and collaborate with local medical centers to implement its treatment technologies.

The company plans to expand its reach into the Middle Eastern market, enhancing its operational footprint and product offerings to adapt to the specific needs of these regions.